Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2) (RAVE2)
A Phase I Open Label Study of the Safety, Tolerability and Efficacy of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)
Sponsor: David M. Brown, M.D.
Terminated
The collaborator, Genentech, stopped supplying the study drug to the site.
Other terminated trials from David M. Brown, M.D.
- Age Related Macular Degeneration · Phase PHASE1/PHASE2 · Jan 2013
- Age-Related Macular Degeneration · Phase PHASE4 · Jan 2009
More terminations from David M. Brown, M.D.
Other Eye Diseases trials with similar outcome
This PHASE1 trial investigates Eye Diseases and Ischemia and is currently terminated or withdrawn. David M. Brown, M.D. leads this study, which shows 7 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
-
Sep 2017 — Jun 2018 [monthly]
Terminated PHASE1
▶ Show 2 earlier versions
-
Feb 2017 — Sep 2017 [monthly]
Terminated PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1
First recorded
Oct 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- David M. Brown, M.D.
- Genentech, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .